Skip to main content
SpringerLink
Log in

Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine

  • Published:
Biotechnology and Bioprocess Engineering Aims and scope Submit manuscript

Abstract

The purpose of the present study was to examine the efficacy and mechanism of the PAB (para-amino benzamidine) affinity column chromatography, Viresolve NFP virus filtration, pasteurization (60°C heat treatment for 10 h), and lyophilization steps employed in the manufacture of urokinase from human urine as regards the removal and/or inactivation of the hepatitis A virus (HAV). Samples from the relevant stages of the production process were spiked with HAV and subjected to scale-down processes mimicking the manufacture of urokinase. Samples were collected at each step, immediately titrated using a 50% tissue culture infectious dose (TCID50), and the virus reduction factors evaluated. PAB chromatography was found to be an effective step for removing HAV with a log reduction factor of 3.24. HAV infectivity was rarely detected in the urokinase fraction, while most of the HAV infectivity was recovered in the unbound and wash fractions. HAV was completely removed during the vire solve NFP filtration with a log reduction factor of ≥4.60. Pasteurization was also found to be an effective step in inactivating HAV, where the titers were reduced from an initial titer of 7.18 log10 TCID50 to undetectable levels within 10 h of treatment. The log reduction factor achieved during pasteurization was ≥4.76. Lyophilization revealed the lowest efficacy for inactivating HAV with a log reduction factor of 1.48. The cumulative log reduction factor was ≥14.08. Accordingly, these results indicate that the production process for urokinase exhibited a sufficient HAV reducing capacity to achieve a high margin of virus safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sherry, S. (1987) Thrombolytic therapy in acute myocardial infarction. A perspective.Drugs 33 (Suppl 3): 1–12.

    Article  Google Scholar 

  2. Coulepis, A. G., S. A. Locarnini, N. I. Lehmann, and I. D. Gust (1980) Detection of hepatitis A virus in the feces of patients with naturally acquired infections.J. Infect. Dis. 141: 151–156.

    CAS  Google Scholar 

  3. Andrewes, C. (1989)Andrewes' Viruses of Vertebrates, pp. 120–145. Balliere Tindal, London, UK.

    Google Scholar 

  4. Borovec, S., C. Broumis, W. Adcock, R. Fang, and E. Uren (1998) Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.Biologicals 26: 237–244.

    Article  CAS  Google Scholar 

  5. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.J. Microbiol. 39: 67–73.

    CAS  Google Scholar 

  6. Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine.Transfusion 39: 1041–1044.

    Article  CAS  Google Scholar 

  7. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).

  8. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability.Federal Resister 63(185): 51074–51084.

    Google Scholar 

  9. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000) Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate.J. Microbiol. 38: 187–191.

    CAS  Google Scholar 

  10. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma.Biotechnol. Bioprocess Eng. 6: 25–30.

    Article  CAS  Google Scholar 

  11. Han, B., J. O. Carlson, S. M. Powers, and S. R. Wickramasinghe (2002) Enhanced virus removal by flocculation and microfiltration.Biotechnol. Bioprocess Eng. 7: 6–9.

    Article  CAS  Google Scholar 

  12. Kim, I. S., Y. W. Choi, S. R. Lee, H. B. Cho, H. G. Eo, H. S. Woo, C. E. Chang, and S. Lee (2001) Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation.J. Microbiol. Biotechnol. 11: 619–627.

    CAS  Google Scholar 

  13. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety: Part 1. General considerations.Bio. Pharm.. February: 32–43.

    Google Scholar 

  14. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma.J. Microbiol. Biotechnol. 11: 497–503.

    CAS  Google Scholar 

  15. Hamman, J., J. Zou, and B. Horowitz (1994). Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates.Vox Sang. 67 (Suppl. 1): 72–77.

    Article  CAS  Google Scholar 

  16. Lemon, S. M., P. C. Murphy, A. Smith, J. Zou, J. Hammon, S. Robinson, and B. Horowitz (1994) Removal/ neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.J. Med. Virol. 43: 44–49.

    Article  CAS  Google Scholar 

  17. Adcock, W. L., A. Macgregor, J. R. Davies, M. Hattarki, D. A. Anderson, and N. H. Goss (1998) Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin.Biotechnol. Appl. Biochem. 28: 85–94.

    CAS  Google Scholar 

  18. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance.Bio. Pharm. February: 32–43.

    Google Scholar 

  19. Aranha-Creado, H., J. Peterson, and P. Y. Huang (1998) Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter.Biologicals 26: 167–172.

    Article  CAS  Google Scholar 

  20. Eibl, J., N. Barrett, T. Hämmerle, and F. Dorner (1996) Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV.Biologicals 24: 285–287.

    Article  CAS  Google Scholar 

  21. Graf, E. G., E. Jander, A. West, H. Pora, and H. Aranha-Creado (1999) Virus removal by filtration.Dev. Biol. Stand. 99: 89–84.

    CAS  Google Scholar 

  22. Oshima, K. H., T. T. Evans-strickfaden, and A. K. Highsmith (1998) Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian, virus 40 using a polyvinylidene fluoride membrane filter.Vox Sang. 75: 181–188.

    Article  CAS  Google Scholar 

  23. Oshima, K. H., T. T. Evans-strickfaden, A. K. Highsmith, and E. W. Ades (1998) The use of a microporus polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.Biologicals 24: 137–145.

    Article  Google Scholar 

  24. Roberts, P. (1997) Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter.J. Virol. Methods 65: 27–31.

    Article  Google Scholar 

  25. Troccoli, N., J. Mclver, A. Losikoff, and J. Poiley (1998) Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.Biologicals 26: 321–329.

    Article  CAS  Google Scholar 

  26. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee (2000) Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma.J. Microbiol. Biotechnol. 10: 858–864.

    CAS  Google Scholar 

  27. Heimburger, N. and H. E. Karges (1989) Strategies to produce virus-safe blood derivatives.Curr. Stud. Hematol. Blood Transfus. 56: 23–33.

    Google Scholar 

  28. Nowak, T., M. Niedrig, D. Bernhardt, and J. Hilfenhaus (1993) Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization.Dev. Biol. Stand. 81: 169–176.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Research Center, Green Cross Plasma Derivatives Company, 449-900, Kyunggi-Do, Korea

    In Seop Kim, Yong Woon Choi, Sung Rae Lee, Yong Kang, Han Sang Woo & Soungmin Lee

  2. Department of Production, Green Cross Biotech Company, 449-900, Kyunggi-Do, Korea

    Kyung Myung Lee & Dae Han Park

Authors
  1. In Seop Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Woon Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung Rae Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyung Myung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dae Han Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Han Sang Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soungmin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to In Seop Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, I.S., Choi, Y.W., Lee, S.R. et al. Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7, 340–346 (2002). https://doi.org/10.1007/BF02933518

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02933518

Keywords

Search

Navigation